{"result": "(\"entity\"<|>NUTRICIÓN PARENTERAL<|>EVENT<|>Nutritional therapy administered intravenously to patients who cannot eat by mouth, requiring careful monitoring and management of electrolytes and caloric intake.)\n##\n(\"entity\"<|>SERVICIO DE FARMACIA<|>ORGANIZATION<|>The Pharmacy Service is responsible for managing medications and nutritional products, ensuring proper administration and storage.)\n##\n(\"entity\"<|>PACIENTES<|>PERSON<|>Patients at risk of refeeding syndrome who require nutritional support and monitoring during parenteral nutrition.)\n##\n(\"entity\"<|>SÍNDROME DE REALIMENTACIÓN<|>EVENT<|>A medical condition that can occur in patients receiving nutritional support, characterized by metabolic disturbances due to rapid refeeding.)\n##\n(\"entity\"<|>TIAMINA<|>ORGANIZATION<|>A vitamin supplement that is crucial for patients at risk of refeeding syndrome, often administered during the first week of parenteral nutrition.)\n##\n(\"entity\"<|>ÁCIDO FÓLICO<|>ORGANIZATION<|>A vitamin supplement that is also important for patients at risk of refeeding syndrome, typically given alongside thiamine.)\n##\n(\"relationship\"<|>PACIENTES<|>SÍNDROME DE REALIMENTACIÓN<|>Patients are at risk of refeeding syndrome when receiving parenteral nutrition, necessitating careful monitoring and prevention measures.<|>8)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL<|>SERVICIO DE FARMACIA<|>The Pharmacy Service is involved in the management and administration of parenteral nutrition to ensure patient safety and efficacy.<|>7)\n##\n(\"relationship\"<|>PACIENTES<|>NUTRICIÓN PARENTERAL<|>Patients require parenteral nutrition for their medical needs, especially when they cannot consume food orally.<|>9)\n##\n(\"relationship\"<|>TIAMINA<|>PACIENTES<|>Thiamine is administered to patients at risk of refeeding syndrome to prevent complications during parenteral nutrition.<|>8)\n##\n(\"relationship\"<|>ÁCIDO FÓLICO<|>PACIENTES<|>Folic acid is given to patients at risk of refeeding syndrome as part of their nutritional support regimen.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: . En caso de no administrarse de inmediato se conservará en nevera (4-8ºC) hasta su administración.\n\nSi se detecta alguna anomalía en la NP se interrumpirá la infusión y se contactará con el Servicio de Farmacia.\n\nNo se añadirán medicamentos en la NP; en caso necesario contactar con el Servicio de Farmacia.\n\n## SÍNDROME DE REALIMENTACIÓN\n\nSe debe identificar a los pacientes en riesgo del síndrome de realimentación, y prevenirlo. Se trata de pacientes que cumplan con:\n---\n• Una o más de las siguientes características:\n    • Índice de masa corporal (IMC) menor a 16 Kg/m2\n    • Pérdida de peso involuntaria mayor del 15% en los últimos 3-6 meses\n    • Escasa o nula ingesta en los últimos 10 días\n    • Niveles bajos de potasio, fósforo o magnesio antes de comenzar con la NP.\n\n• Dos o más de los siguientes características:\n    • IMC menor de 18 Kg/m2\n    • Pérdida de peso involuntaria mayor del 10% en los últimos 3-6 meses.\n    • Escasa o nula ingesta en los últimos 5 días.\n    • Abuso de alcohol o drogas.\n\n• Pacientes en riesgo:\n    • Anorexia nerviosa\n    • Desnutrición\n    • Ancianos\n    • Enfermedades crónicas\n    • Alcoholismo o drogadicción\n    • Alto grado de estrés metabólico sin ingesta en más de 7 días\n    • Síndromes de mala absorción\n    • Tratamiento prolongado con antiácidos (sales de aluminio y magnesio)\n\n• Medidas de prevención:\n    • Calcular los aportes según el peso real del paciente\n    • Corregir el déficit de electrolitos antes del inicio de la NP\n    • Comenzar con el 25% de las necesidades calóricas y proteicas el primer día, y el 100% de las necesidades de micronutrientes desde el principio, sobretodo en el caso de tiamina, potasio y zinc.\n    • Controlar al principio los aportes de sodio y líquidos (1.000-1.200 ml/día).\n    • Incrementar los aportes progresivamente cada 24-48 horas según evolución hasta alcanzar las necesidades en 3-5 días.\n---\n• Durante los primeros 5-7 días suplementar con tiamina (50-100 mg/día, oral o intravenoso) y ácido fólico (1 mg/día) en los pacientes de riesgo.\n\n• Monitorizar durante la primera semana, en especial, el potasio, fósforo y magnesio.\n\nRetirada de la NP:\n\n• Se realizará gradualmente para evitar complicaciones metabólicas, durante 48-72 horas, cuando el paciente tolere más de 1000 Kcal por vía enteral durante al menos 3 días.\n\n• Tras la retirada de la NP vigilar y adoptar medidas para prevenir el riesgo de hipoglucemias. En caso de suspensión brusca de la NP se infundirá glucosa 10 % al mismo ritmo de infusión que la NP.\n\n• Las bolsas no administradas de NP se remitirán al Servicio de Farmacia, guardándose en el frigorífico hasta su devolución.\n\nNUTRICIÓN PARENTERAL PERIFÉRICA\n\nLa NPPs se encuentran disponibles en el stock de planta como el caso de la fluido terapia. Se trata de fórmulas estándares comercializadas y por tanto de composición fija.\n\nSe debe seguir las mismas recomendaciones que la NPT. Se utilizaran también para su administración bombas de infusión a una velocidad máxima de 40 gotas/min. Cambiar el catéter venoso en NP periférica cada 48 horas en el caso de adultos, para evitar flebitis y colonización.\n\nEn NPP es recomendable el empleo de un protocolo específico de prevención y diagnóstico precoz de tromboflebitis por catéter.\n\nADMINISTRACIÓN CÍCLICA\n\nEl cambio de NP a NP cíclica puede realizarse en pacientes que necesitan NP durante más de 2 semanas\n\n• Se debe disminuir progresivamente el tiempo de infusión de la NP durante 3-4 días.\n\n• Debe haber un periodo de incremento progresivo del ritmo de infusión al inicio, para evitar cambios bruscos en la glucemia, así como un periodo de reducción del ritmo al final de la infusión.\n---\n• Se controlará la glucemia una hora después de alcanzar la velocidad de infusión de mantenimiento, y una después de finalizar la administración de la NP.\n\n• Si aparece hiperglucemia al inicio o hipoglucemia tras la retirada de la NP, se incrementará la duración del periodo de aumento-disminución del ritmo de infusión o se prolongará la duración de la administración.\n\n## 5. SEGUIMIENTO Y CONTROL DEL PACIENTE CON NP\n\nEl seguimiento y control del paciente debe realizarse de forma periódica con la finalidad de valorar la efectividad de los a\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}